UNCY DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCYGlobeNewsWire · 12 hr ago
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitGuruFocus · 20 hr ago
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitPRNewsWire · 21 hr ago
UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026Newsfile Corp · 22 hr ago
UNCY DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCYNewsfile Corp · 1 day ago
What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff DeadlineGuruFocus · 1 day agoUnicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.47 | -$0.06 | Beat |
| May 12, 2026 | -$0.55 | -$0.54 | Beat |
| Mar 30, 2026 | -$0.46 | -$0.82 | Miss |
| Nov 12, 2025 | -$0.59 | -$0.33 | Beat |
| Aug 14, 2025 | -$0.70 | -$0.52 | Beat |
| May 14, 2025 | -$0.67 | -$0.50 | Beat |